Vidcast: https://www.instagram.com/p/DTdqupiEeau/

Maternal RSV vaccination during pregnancy and the use of the RSV antibody nirsevimab for newborns reduces the incidence of RSV infections by more than two-thirds. Researchers at the CDC and leading children’s hospitals studied 5,029 babies during the 2024–2025 RSV season and published their results in the journal JAMA Pediatrics.

Among infants younger than six months, maternal RSV vaccination was 70% effective and nirsevimab was 81% effective. RSV hospitalization rates were reduced 41% to 51% among newborns and infants compared with previous rates. The highest reduction of 56% to 63% occurred in newborns and infants aged 0 to 2 months

When RSV vaccinations and antibody injections were rolled out nationally, RSV hospitalizations among infants under one year fell by up to half. The largest reduction was seen in newborns and babies under two months, the group at highest risk for severe RSV.

Bottom line: mothers….protect your babies with these safe and very effective interventions.

https://www.medscape.com/viewarticle/maternal-rsv-vaccine-and-nirsevimab-show-effectiveness-us-2026a10000ah

https://jamanetwork.com/journals/jamapediatrics/article-abstract/2843213

#rsv #newborns #vaccine #nirsevimab #hospitalization